Home > Insider Trading > Filing (0001209191-21-055663)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1549595	Nurix Therapeutics Inc.	NRIX	Pharmaceutical Preparations (2834)	270838048

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1817199	Christine Ring	C/O Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco CA 94158	General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-09-10	2,000	$1.86	3,286	No	4	M	Direct
Common Stock	Disposition	2021-09-10	700	$35.10	2,586	No	4	S	Direct
Common Stock	Disposition	2021-09-10	500	$35.77	2,086	No	4	S	Direct
Common Stock	Disposition	2021-09-10	800	$36.76	1,286	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2021-09-10	2,000	$0.00	2,000	$1.86

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
105,666		2029-09-30	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
Represents the weighted average sale price. The lowest price at which shares were sold was $34.58 and the highest price at which shares were sold was $35.53. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
Represents the weighted average sale price. The lowest price at which shares were sold was $35.64 and the highest price at which shares were sold was $35.90.
The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.